TG Therapeutics is a biopharmaceutical company that develops and commercializes treatments for B-cell diseases and multiple sclerosis, including its anti-CD20 therapy.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 63 | New buy | 173,120 | $9,511,213 | 0.0% |
| Steve Cohen / Point72 | 76 | New buy | 367,163 | $20,171,935 | 0.0% |
| Bridgewater | 56 | Added +38% | 429,904 | $23,618,926 | 0.1% |
| Ancora | 40 | Holds (flat) | 300 | $16,482 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-09-22 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-07-01 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-05-14 | Trump, Donald J President | SELL | $15.001 - $50,000 | PTR |
| 2026-05-14 | Trump, Donald J President | BUY | $50,001 - $100,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.